Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > COMMENTARY
COMMENTARY
- Type 2 Diabetic Mellitus: Expanding Therapeutics Strategy (2)
June 27, 2005
- Type 2 Diabetic Mellitus: Expanding Therapeutics Strategy (1)
June 20, 2005
- Special Contribution
May 16, 2005
- Japan's Most Admired Pharma Companies P. Reed Maurer President, NPP
April 18, 2005
- PRTM Shows Results of Investigational Drug Survey
March 14, 2005
- <Special Comtribution>
March 7, 2005
- <Special Comtribution>
March 7, 2005
- JPMA Update (12)
November 22, 2004
- JPMA Pudate(11)
November 15, 2004
- JPMA Update (10)
November 8, 2004
- JPMA Update (9)
November 1, 2004
- JPMA Update (8)
October 25, 2004
- JPMA Update (7)
October 18, 2004
- JPMA Update (6)
October 11, 2004
- <Special Contribution>
October 4, 2004
- JPMA Update (5)
October 4, 2004
- JPMA Update(4)
September 27, 2004
- JPMA Update (3)
September 20, 2004
- JPMA Update (2)
September 13, 2004
- <New Series>
September 6, 2004
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…